Vyne Therapeutics Inc Total Liabilities
Vyne Therapeutics Inc total liabilities. Based on the latest financial reports, Vyne Therapeutics Inc (VYNE) has total liabilities worth $2.40 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Vyne Therapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Vyne Therapeutics Inc (2015–2025)
Total liabilities of Vyne Therapeutics Inc from 2015 to 2025. This chart illustrates how Vyne Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Vyne Therapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Vyne Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Vyne Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Verde Clean Fuels Inc.
NASDAQ:VGAS
|
USA | $1.57 Million |
|
Sin Heng Chan (Malaya) Bhd
KLSE:4316
|
Malaysia | RM205.23 Million |
|
Circle8 Group, Inc.
NASDAQ:CIRC
|
USA | $926.31 Million |
|
Tekom Technologies
TWO:6294
|
Taiwan | NT$891.89 Million |
|
Accent Resources NL
AU:ACS
|
Australia | AU$22.86 Million |
|
Microfriend Inc
KQ:147760
|
Korea | ₩37.56 Billion |
|
Kingsmen Resources Ltd
V:KNG
|
Canada | CA$50.53K |
|
Equippp Social Impact Technologies Limited
NSE:EQUIPPP
|
India | Rs-150.72 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Vyne Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VYNE total asset value.
Liquidity & Leverage Metrics
Vyne Therapeutics Inc Total Liabilities Ratios Explained
Vyne Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vyne Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vyne Therapeutics Inc (2015–2025)
The table below shows the annual total liabilities of Vyne Therapeutics Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.40 Million | -83.84% |
| 2024-12-31 | $14.82 Million | +65.58% |
| 2023-12-31 | $8.95 Million | -6.34% |
| 2022-12-31 | $9.56 Million | -48.09% |
| 2021-12-31 | $18.41 Million | -67.27% |
| 2020-12-31 | $56.25 Million | +427.61% |
| 2019-12-31 | $10.66 Million | +11.62% |
| 2018-12-31 | $9.55 Million | -92.29% |
| 2017-12-31 | $123.90 Million | +73.30% |
| 2016-12-31 | $71.49 Million | +19.48% |
| 2015-12-31 | $59.84 Million | -- |
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pa… Read more